Connect Biopharma Holdings Limited Share-based Payment Arrangement, Expense
Connect Biopharma Holdings Limited (CNTB) reported Share-based Payment Arrangement, Expense of $1.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-12
- Connect Biopharma Holdings Limited share-based payment arrangement, expense for the quarter ending 2026-06-30 was $1.26M, a 32.60% increase year-over-year.
- Connect Biopharma Holdings Limited share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.20M, a 27.28% increase year-over-year.
- Connect Biopharma Holdings Limited share-based payment arrangement, expense for the quarter ending 2025-12-31 was $917.00K, a 34.55% decline year-over-year.
- Connect Biopharma Holdings Limited share-based payment arrangement, expense for the quarter ending 2025-09-30 was $916.00K, a 54.70% decline year-over-year.
- Connect Biopharma Holdings Limited share-based payment arrangement, expense for fiscal 2025 was $3.73M, a 44.62% decline from fiscal 2024.
- Connect Biopharma Holdings Limited share-based payment arrangement, expense for fiscal 2024 was $6.73M, a 24.68% increase from fiscal 2023.
- Connect Biopharma Holdings Limited share-based payment arrangement, expense for fiscal 2023 was $5.40M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.26M 10-Q · filed 2026-08-12 | $2.46M 10-Q · filed 2026-08-12 | $3.38M derived: sum of 3 quarters · filed 2026-08-12 | $4.29M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-12 | $2.12M derived: sum of 2 quarters · filed 2026-05-12 | $3.03M derived: sum of 3 quarters · filed 2026-05-12 | $3.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $917.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.83M derived: sum of 2 quarters · filed 2026-03-31 | $2.78M derived: sum of 3 quarters · filed 2026-08-12 | $3.73M 10-K · filed 2026-03-31 |
| 2025-09-30 | $916.00K 10-Q · filed 2025-11-12 | $1.87M derived: sum of 2 quarters · filed 2026-08-12 | $2.81M 10-Q · filed 2025-11-12 | $4.21M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $951.00K 10-Q · filed 2026-08-12 | $1.89M 10-Q · filed 2026-08-12 | $3.29M derived: sum of 3 quarters · filed 2026-08-12 | $5.32M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $942.00K 10-Q · filed 2026-05-12 | $2.34M derived: sum of 2 quarters · filed 2026-05-12 | $4.37M derived: sum of 3 quarters · filed 2026-05-12 | $6.35M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.42M derived: sum of 2 quarters · filed 2026-03-31 | $5.41M derived: sum of 3 quarters · filed 2026-03-31 | $6.73M 10-K · filed 2026-03-31 |
| 2024-09-30 | $2.02M 10-Q · filed 2025-11-12 | $4.01M derived: sum of 2 quarters · filed 2025-11-12 | $5.33M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $1.99M 10-Q · filed 2025-08-13 | $3.31M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $1.32M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $5.40M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |